Featuring: Amy Heimberger, MD
Man's best friend is helping scientists find new treatments for brain tumors. Amy Heimberger, MD, is a board-certified neurosurgeon with extensive training and experience in the field of immunology. She is part of a promising new study in canine glioblastoma that could lead to more effective human glioblastoma clinical trials.
Heimberger was part of a team that conducted a Phase I clinical trial at the Texas A&M College of Veterinary Medicine & Biomedical Sciences Veterinary Medical Teaching Hospital. Investigators injected an immunotherapy drug known as a STING (STimulator of INterferon Genes) agonist directly into the glioblastoma tumors of six dogs.
Some of the dogs, even with a single dose, responded to the treatment with apparent reductions in their tumor volume, including one complete radiographic response, meaning the tumor completely disappeared. The findings, published in Clinical Cancer Research lead the team to conclude this therapy can trigger a robust, innate anti-tumor immune response and may be highly effective on recalcitrant tumors such as glioblastoma in humans.
Topics covered in this show:
Recorded on March 29, 2022
Continuing Medical Education Credit
Physicians may claim continuing medical education credit after listening to an episode of this program.
Claim your credit >
This podcast was originally released by Northwestern University Feinberg School of Medicine on April 22, 2022.
Amy Heimberger, MD , Jean Malnati Miller Professor of Brain Tumor Research
Northwestern Medicine welcomes the opportunity to collaborate with you on the care of your patients.